Beamion PANTUMOR-1: A Phase II multicentre multicohort open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours (1479-0009)
Learn More About This Study
